Everlum Bio

IMPORTANT RARE DISEASE DAY NEWS I know it seems impossible to think, but Rare Disease Day 2025 is only 7 months away which means the RARE Rev team are now turning our attention to our RDD strategy, and it is time you do too. Last year RARE Revolution Magazine reached over 4.5 million people with our RDD issue alone and 2025 is going to be bigger and better, so you do not want to miss out on this opportunity to get your organisation at the forefront of our activities. So we are pleased to announce that our 2025 RDD flagship issue and RDD RARE Rev-inar is now open for booking! To find out how to secure our prime 2025 opportunity email [email protected] to arrange a call. Check out our RDD 24 issue here: https://lnkd.in/edYFXmed #RareDiseaseDay2015

Clinical trials for rare diseases face unique hurdles - small patient pools and limited historical data. But by collaborating closely with the FDA early on, we can develop trial designs, endpoints, and analysis methods tailored to the disease at hand. This personalized approach is key to advancing treatments for these underserved conditions. Reach out to us here at everlum.bio to discuss validation solutions that can work for you! #clinicaltrials #rarediseases #fdacollaboration #drugdevelopment #validation #progress #personalizedmedicine

NORD’s #NeurotrophicKeratitis Patient Assistance Program offers individuals with NK financial support for out-of-pocket healthcare costs related to the care and treatment of this diagnosis. Apply online: https://bit.ly/4f7H0ug or email [email protected]

We are living and innovating in truly remarkable times. Not just witnessing the transformative potential of precision medicine, but directly impacting it. The rapid evolution of this field is a testament to the power of innovation and scientific advancement to reshape healthcare as we know it.

NORD offers financial assistance for patients with #CTX, or #CerebrotendinousXanthomatosis, to help pay for out-of-pocket medical costs. Email [email protected] or apply online here: https://bit.ly/3LdBIzJ

The validation step of our drug discovery phase in Everlum Bio’s Cure Plan is where we put our promising drug candidates through the wringer, verifying and confirming their potential before they can advance to clinical trials. It's all about ensuring the initial results are reliable, reproducible, and have a real shot at becoming safe and effective treatments for each patient. And when it comes to rare diseases, the proof-of-concept phase is equally essential. This is where we demonstrate the feasibility and potential effectiveness of our novel therapeutic approaches. Want to see if Everlum can do this for you? Contacting us at everlum.bio today! #DrugDevelopment #PreclinicalResearch #RareDiseaseInnovation #Validation #RapidProofof Concept #PersonalizedMedicine #JourneyToACure

#NewbornScreening panels can vary from state to state and are updated every year. So what is the current state of newborn screening in America today? Our 2024 #LivingRareForum panelists discussed this: https://lnkd.in/emCAt_iN Feat. ALD Alliance/Aidan Jack Seeger Foundation, Speragen #RareDisease #RareDiseases

NORD's #PKU Patient Assistance Program offers financial support for out-of-pocket healthcare costs related to #phenylketonuria care and treatment. Email [email protected] or apply online here: https://bit.ly/4czUzRE

Limited to just one treatment option or no option at all? Let Everlum Bio take a look! Our approach to rare diseases is truly modality-agnostic, meaning we're open to leveraging a wide range of technologies to tackle the problem. Small molecules, antisense oligos, gene therapy , etc. Using a multiple modality approach is essential because when it comes to rare conditions, we believe every option should be on the table. Let Everlum's modality-agnostic approach drive innovation for you! Contact us to learn how at everlum.bio ! #RareDiseases #MultiModalTherapy #MedicalResearch #PersonalizedMedicine

I am SO excited to share this portion of the article from #MDA #QuestMagazine about the current work being done at the preclinical level for #HMERF research. Our Foundation is working with leading geneticists and leading scientists looking for breakthrough strategies with Everlum Bio !! Please support our effort by donating thru this link. Our next phase needs $75,000 to continue our work and we need your help more than ever. https://lnkd.in/eCVqypGn